Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.

Abstract:

:The aim of this study was to both develop and validate a nomogram based on the Ki-67 index to predict recurrence. We constructed a nomogram using the Cox proportional hazards model with 953 N0 and N1 postoperative hormone receptor (HR)-positive breast cancer patients and validated it in an external cohort of 895 patients. A prognostic model that used classical variables, Adjuvant! Online, St. Gallen risk stratification, and the four immunohistochemistry (IHC) markers (IHC4 score) was created and assessed by the likelihood ratio χ(2) (LR-χ(2)) test using the bootstrapping method. The nomogram showed an area under the receiver operating characteristic curve (AUC) of 0.75 (95% CI 0.72-0.77) in the training set. The validation set showed good discrimination with an AUC of 0.63 (95% CI 0.60-0.66). In the LR-χ(2) test, the nomogram score was found to be more informative than the IHC4 with clinical score (CS) [LR-χ(2) 13.365 (1 d.f.); 95% CI 2.50-24.23 for CS-IHC4 + nomogram score vs. CS-IHC4] on distant recurrence-free survival. This study implies that the amount of prognostic information contained in the nomogram is superior to that in the CS-IHC4 score in HR-positive N0 and N1 breast cancer patients (NCT1273415).

journal_name

Oncology

journal_title

Oncology

authors

Park YH,Im SA,Cho EY,Ahn JH,Woo SY,Kim S,Keam B,Lee JE,Han W,Nam SJ,Park IA,Noh DY,Yang JH,Ahn JS,Im YH

doi

10.1159/000362281

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

279-88

issue

5-6

eissn

0030-2414

issn

1423-0232

pii

000362281

journal_volume

86

pub_type

杂志文章

相关文献

ONCOLOGY文献大全
  • Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer.

    abstract:OBJECTIVE:Ovarian cancer is the most lethal gynecological malignancy, but information relevant to prognosis and outcomes remain unknown. Here, we used statistical methods to focus specifically on interactions between candidate prognostic variables. METHODS AND RESULTS:Univariate, multivariate, and elastic net modeling...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000442710

    authors: Jatoi A,Vierkant RA,Hawthorne KM,Block MS,Ramus SJ,Larson NB,Fridley BL,Goode EL

    更新日期:2016-01-01 00:00:00

  • Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer.

    abstract:OBJECTIVE:We conducted this study to compare tumor measurement by computed tomography (CT) and tumor response assessment between Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 and RECIST 1.1 in patients with metastatic colorectal cancer (CRC). METHODS:We reviewed the medical records of patients with metasta...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000357714

    authors: Jang HJ,Kim BC,Kim HS,Kim JH,Song HH,Kim JB,Park JJ,Yoon SN,Woo JY,Zang DY

    更新日期:2014-01-01 00:00:00

  • Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.

    abstract:OBJECTIVE:The aim of this study was to investigate the outcomes of gemcitabine-treated patients with inoperable biliary tract cancers. METHODS:We conducted a retrospective study of consecutively treated 22 inoperable biliary tract cancer patients with gemcitabine (500-1,000 mg/m(2) on days 1, 8, 15 every 4 weeks) as f...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000098109

    authors: Kiba T,Nishimura T,Matsumoto S,Hatano E,Mori A,Yasumi S,Doi R,Ikai I,Kitano T,Nishimura T,Yoshikawa K,Ishiguro H,Yanagihara K,Doi E,Teramukai S,Fukushima M

    更新日期:2006-01-01 00:00:00

  • Relapse of Hodgkin's disease after ten years.

    abstract::We report four cases of Hodgkin's disease (HD) relapsing after complete remission for over a 10-year period after the initial therapy. Three of the patients had mixed-cellularity subtypes as a primary histological diagnosis, and the rebiopsies demonstrated mixed cellularity in all very late relapse cases. Two patients...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227474

    authors: Illés A,Bányai A,Vadász G,Szegedi G

    更新日期:1995-07-01 00:00:00

  • DNA-Sensing and Nuclease Gene Expressions as Markers for Colorectal Cancer Progression.

    abstract:OBJECTIVE:Oncogene-driven stress-related DNA damage has been observed in lesions of colon cancer. Furthermore, DNA sensors and nucleases are stimulated during active DNA damage and replication. However, their changes and influences with respect to cancer remain largely unknown. METHODS:The gene expression levels of cG...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000452281

    authors: Yang CA,Huang HY,Chang YS,Lin CL,Lai IL,Chang JG

    更新日期:2017-01-01 00:00:00

  • Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status.

    abstract:OBJECTIVES AND METHODS:The association oxaliplatin (OXA)-5-fluorouracil/folinic acid (FUFA) is currently a standard first-line treatment for advanced colorectal cancer. The main objective of this experimental study was to examine the cytotoxic effects resulting from the addition of ionizing radiation (Rgamma) to the co...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000069308

    authors: Magné N,Fischel JL,Formento P,Etienne MC,Dubreuil A,Marcié S,Lagrange JL,Milano G

    更新日期:2003-01-01 00:00:00

  • Effect of canthaxanthin on chemically induced mammary carcinogenesis.

    abstract::Canthaxanthin, a carotenoid with no vitamin A activity, was evaluated for its efficacy in the prevention of chemically induced mammary cancers. Canthaxanthin was administered in the diet at two dose levels (3,390 or 1,130 mg/kg diet). In the dimethylbenzanthracene-induced mammary cancer model, diet supplementation wit...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226935

    authors: Grubbs CJ,Eto I,Juliana MM,Whitaker LM

    更新日期:1991-01-01 00:00:00

  • A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.

    abstract:OBJECTIVE:We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin chemotherapy in early-stage ovarian carcinoma. METHODS:Fifty-three patients were treated according to the risk of relapse: patients with stages IA or IB or with grade 1 (low risk) received 4 cycles of paclitaxel and carboplatin; pat...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000334230

    authors: Bamias A,Bamia C,Karadimou A,Soupos N,Zagouri F,Rodolakis A,Haidopoulos D,Vlahos G,Thomakos N,Antsaklis A,Dimopoulos MA

    更新日期:2011-01-01 00:00:00

  • Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.

    abstract:BACKGROUND:Transcatheter arterial chemoembolization (TACE) is a standard therapy used in the treatment of intermediate hepatocellular carcinoma (HCC). Recently, balloon-occluded TACE (B-TACE) has been developed. PURPOSE:This study aimed to clarify the effects of B-TACE in patients with HCC, with a focus on which drug ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000492822

    authors: Shirono T,Iwamoto H,Niizeki T,Shimose S,Nakano M,Satani M,Okamura S,Noda Y,Kamachi N,Kuromatsu R,Sakai M,Nomiyama M,Kuwano T,Tanaka M,Koga H,Torimura T

    更新日期:2019-01-01 00:00:00

  • Role of the basement membrane in tumor cell dormancy and cytotoxic resistance.

    abstract:OBJECTIVES AND METHODS:Tumor dormancy and resistance to cytotoxic agents are key limiting events in the treatment of malignant diseases. To determine whether both are influenced by the extracellular milieu in which tumors reside, HT1080 human fibrosarcoma, MCF-7 breast carcinoma and OSCORT osteosarcoma cell proliferati...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000055329

    authors: Pogány G,Timár F,Oláh J,Harisi R,Polony G,Paku S,Bocsi J,Jeney A,Laurie GW

    更新日期:2001-01-01 00:00:00

  • Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.

    abstract::The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this setting, prompted us to investigate the effectiveness of a carboplatin-containing regimen in a p...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000011890

    authors: Briasoulis E,Tsavaris N,Fountzilas G,Athanasiadis A,Kosmidis P,Bafaloukos D,Skarlos D,Samantas E,Pavlidis N

    更新日期:1998-09-01 00:00:00

  • Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.

    abstract::In squamous cell carcinoma of the head and neck (SCCHN), hypoxia is considered a crucial physiological modulator for malignant progression, wherebythe plasminogen activation system is involved in overlapping functions such as moulding of the extracellular matrix, cell proliferation and signal transduction. Little is k...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000106789

    authors: Sprague LD,Mengele K,Schilling D,Geurts-Moespot A,Sweep FC,Stadler P,Schmitt M,Molls M

    更新日期:2006-01-01 00:00:00

  • Implications of flow cytometry in preoperative detection of biologic variables of gastric cancer and malignant condition of gastric remnant cells obtained by endoscopic biopsy.

    abstract::Flow cytometric (FCM) DNA studies were performed on cell suspensions obtained by endoscopic biopsy in 73 patients with gastric cancer and in 61 patients with gastric remnant. In cancer, DNA aneuploidies were detected in 49 tumors (67.1%), including 51.7% (15/29) of early gastric cancers and 77.3% (34/44) of advanced g...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227389

    authors: Kimura H,Kanno M,Takamura H,Arakawa H,Maeda K,Uogishi M,Sodani H,Kawashima T

    更新日期:1994-11-01 00:00:00

  • Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.

    abstract:OBJECTIVE:We evaluated the efficacy and safety of bolus 5-fluorouracil (5-FU) and leucovorin combined with weekly paclitaxel (FLTAX) in advanced gastric cancer (GC) patients. METHODS:Patients with untreated stage IV GC received paclitaxel 80 mg/m(2) as a 1-hour infusion, followed by 5-FU 600 mg/m(2) as a bolus infusio...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000334462

    authors: Matsubara J,Shimada Y,Kato K,Nagai Y,Iwasa S,Nakajima TE,Hamaguchi T,Yamada Y,Takagi S,Kobayashi K,Yoshioka A,Nakayama N,Tsuji A

    更新日期:2011-01-01 00:00:00

  • The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.

    abstract:OBJECTIVES:A germline BIM deletion polymorphism has been proposed to predict a poor treatment efficacy of certain kinase inhibitors. The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC). METHODS:All patients wh...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000356019

    authors: Shao YY,Chang YL,Huang CY,Hsu CH,Cheng AL

    更新日期:2013-01-01 00:00:00

  • Phase II evaluation of Ly156758 in metastatic breast cancer.

    abstract::Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treat...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226637

    authors: Buzdar AU,Marcus C,Holmes F,Hug V,Hortobagyi G

    更新日期:1988-01-01 00:00:00

  • Bone scintigrams: their clinical usefulness in patients with breast carcinoma.

    abstract::A comparison of bone scintigrams and roentgenographic skeletal surveys, obtained on 170 patients with breast carcinoma, was made to evaluate the diagnostic efficacy of these techniques in detecting metastatic bone lesions. The bone scans were abnormal in 81 patients, while the roentgenograms were abnormal in only 51. ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225325

    authors: Joo KG,Parthasarathy KL,Bakshi SP,Rosner D

    更新日期:1979-01-01 00:00:00

  • Prognostic value of syndecan-1 expression in breast cancer.

    abstract:OBJECTIVE:Syndecan-1 is a cell surface heparan sulphate proteoglycan which participates in cell proliferation, cell migration and cell-matrix interactions. Epithelial syndecan-1 expression is reduced in several malignant tumours, but in breast and pancreatic cancer, increased expression has also been described. Loss of...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000080280

    authors: Leivonen M,Lundin J,Nordling S,von Boguslawski K,Haglund C

    更新日期:2004-01-01 00:00:00

  • Phase-I clinical trial of sodium cyanate in patients with advanced colorectal carcinoma.

    abstract::Sodium cyanate, a drug that selectively suppresses amino acid incorporation for protein synthesis in tumor tissue, was given to patients with advanced colorectal carcinoma who had failed to conventional therapy, with the purpose of assessing a maximum tolerable oral dose. At 35 mg/kg p.o. daily, the drug had to be sto...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226038

    authors: Herrera-Ornelas L,Petrelli NJ,Madajewicz S,Mittelman A,Allfrey VG

    更新日期:1985-01-01 00:00:00

  • Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.

    abstract:PURPOSE:Breast cancers expressing high levels of Ki-67, a nuclear marker of cell proliferation, are associated with worse outcome. Recent data from neoadjuvant studies indicate that a single measurement of the nuclear proliferation marker Ki-67 in breast carcinoma during neoadjuvant therapy is strongly predictive of lo...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000322189

    authors: Miglietta L,Vanella P,Canobbio L,Naso C,Cerisola N,Meszaros P,Parodi MA,Morabito F

    更新日期:2010-01-01 00:00:00

  • High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer.

    abstract::High-dose megestrol acetate (800 mg/day) was administered to 34 patients as third-line endocrine therapy for metastatic breast cancer after progression on standard-dose megestrol acetate (160 mg/day). Among the 32 evaluable patients, no complete or partial response occurred. Ten patients remained stable and 22 progres...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1159/000227119

    authors: Cruz JM,Muss HB,Russell G

    更新日期:1992-01-01 00:00:00

  • Assessment of an in vitro screening test of cytotoxic agents in the treatment of advanced malignant disease.

    abstract::The value of a screening test for sytoxic chemotherapeutic agents in the treatment of advanced malignant disease is assessed by comparing the performances of 32 patients whose treatment followed closely the test recommendations with that of 31 patients whose treatment did not follow the predictions. The significant im...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000224977

    authors: Wheeler TK,Dendy PP,Dawson A

    更新日期:1974-01-01 00:00:00

  • Clinical characteristics and outcomes of lung cancer with pulmonary embolism.

    abstract:BACKGROUND:Cancer patients have a higher risk for thrombosis that is usually related to advanced stage and poor prognosis. This study aimed to identify the clinical picture and outcome of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients with pulmonary embolism (PE). PATIENTS AND METHODS:Fr...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000229503

    authors: Chuang YM,Yu CJ

    更新日期:2009-01-01 00:00:00

  • Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.

    abstract:OBJECTIVE:Irinotecan has, in general, been administered as a 90-min infusion. However, several studies have demonstrated that continuous infusion seems to be a promising method of delivering irinotecan. This phase I/II trial was performed to evaluate the efficacy and safety of continuous infusion of irinotecan combined...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000209963

    authors: Sadahiro S,Suzuki T,Maeda Y,Tanaka A,Ishikawa K,Makuuchi H,Murayama C

    更新日期:2009-01-01 00:00:00

  • Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses.

    abstract:OBJECTIVES:Calcitriol, 1alpha,25-dihydroxyvitamin D(3) (1,25-D(3)) has potent antiproliferative effects and potentiates the antitumor activity of many other cytotoxic drugs. 1,25-D(3) plasma pharmacokinetic (PK) parameters associated with antitumor activity in experimental animal models are unknown. The objective of th...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000076336

    authors: Muindi JR,Modzelewski RA,Peng Y,Trump DL,Johnson CS

    更新日期:2004-01-01 00:00:00

  • Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases.

    abstract:PURPOSE:To confirm the safety and effectiveness of techniques to assist radiofrequency ablation (RFA) for difficult cases, we retrospectively evaluated successful treatment rates, early complications and local tumor progressions. PATIENTS AND METHODS:Between June 1999 and April 2009, a total of 341 patients with 535 n...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000315236

    authors: Inoue T,Minami Y,Chung H,Hayaishi S,Ueda T,Tatsumi C,Takita M,Kitai S,Hatanaka K,Ishikawa E,Yada N,Hagiwara S,Ueshima K,Kudo M

    更新日期:2010-07-01 00:00:00

  • Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy.

    abstract::The antiemetic effect of graded, single high-dose intravenous dexamethasone was studied in 27 patients receiving combination chemotherapy with either doxorubicin (50 mg/m2) or cis-platinum (100 mg/m2). A total of 57 cycles were individually evaluated, utilizing a detailed rating system. Nausea and vomiting did not occ...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000226099

    authors: Zaglama NE,Rosenblum SL,Sartiano GP,Brady M,Gonzalez MF,Valdivieso JG

    更新日期:1986-01-01 00:00:00

  • Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.

    abstract:BACKGROUND:Patients with localized esophageal and esophagogastric junction cancer (EAC) receive chemoradiation and then surgery (trimodality, TMT) or definitive chemoradiation (bimodality, BMT). Distant metastases (DMs) are common but the details of their distribution and timing in a large cohort have not been describe...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000360703

    authors: Shiozaki H,Sudo K,Xiao L,Wadhwa R,Elimova E,Hofstetter WL,Skinner HD,Lee JH,Weston B,Bhutani MS,Blum MA,Maru DM,Ajani JA

    更新日期:2014-01-01 00:00:00

  • Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas.

    abstract::A pilot study was performed administering PCNU with radiation therapy to treat patients with high-grade astrocytomas and to explore the toxic effects of this drug regimen. PCNU at an initial dose of 110 mg/m2 i.v. was administered to 14 patients within 4 weeks after completion of cranial irradiation. Courses were repe...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226854

    authors: Feun LG,Maor M,Stewart DJ,Leavens ME,Savaraj N,Bodey GP

    更新日期:1990-01-01 00:00:00

  • Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation.

    abstract:OBJECTIVE:The purpose of this study was to investigate the longitudinal changes in quality of life (QoL) for patients with advanced stage (stage III or IV) head and neck squamous cell carcinoma (HNSCC) following primary radiotherapy (RT) or concomitant chemoradiotherapy. METHODS:From January 2001 to January 2003, 149 ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000086982

    authors: Fang FM,Tsai WL,Chien CY,Chiu HC,Wang CJ,Chen HC,Hsiung CY

    更新日期:2005-01-01 00:00:00